
[Federal Register Volume 81, Number 121 (Thursday, June 23, 2016)]
[Notices]
[Pages 40889-40890]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-14827]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]


Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory 
Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of meeting of the Pediatric Oncology 
Subcommittee of the Oncologic Drugs Advisory Committee. This meeting 
was announced in the Federal Register of June 16, 2016. The amendment 
is being made to reflect a change in the Procedure portion of the 
document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Lauren D. Tesh, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, email: ODAC@fda.hhs.gov; or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area). Please call the Information Line for up-to-date 
information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of June 16, 2016, 81 
FR 39274, FDA announced that a meeting of the Pediatric Oncology 
Subcommittee of the Oncologic Drugs Advisory Committee would be held on 
June 28 and 29, 2016. On page 39274, in the third column, the Procedure 
portion of the document is changed to read as follows:

[[Page 40890]]

    FDA regrets that it was unable to publish this notice 15 days prior 
to the June 28 and 29, 2016, Pediatric Oncology Subcommittee of the 
Oncologic Drugs Advisory Committee meeting. Because the Agency believes 
there is some urgency to bring these issues to public discussion and 
qualified members of the Pediatric Oncology Subcommittee of the 
Oncologic Drugs Advisory Committee meeting were available at this time, 
the Commissioner of Food and Drugs concluded that it was in the public 
interest to hold this meeting even if there was not sufficient time for 
the customary 15-day public notice.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: June 16, 2016.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2016-14827 Filed 6-22-16; 8:45 am]
 BILLING CODE 4164-01-P


